Insulin Icodec Medicine 07 December 2022 Extended indication treatment of diabetes mellitus in adults Therapeutic value Possible benefit in ease of use Total cost Registration phase Registration application pending Product Active substance Insulin Icodec Domain Metabolism and Endocrinology Reason of inclusion New medicine (specialité) Main indication Diabetes Extended indication treatment of diabetes mellitus in adults Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Novo Nordisk Portfolio holder Novo Nordisk Mechanism of action Insulin preparation Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Eenmaal wekelijkse dosering Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date April 2023 Expected Registration May 2024 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value Possible benefit in ease of use This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a week Dosage per administration References NCT04880850; NCT04848480 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Gipdatabank Additional remarks In 2016 waren er 446.462 gebruikers van insuline (totaal van 12 verschillende producten). Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks